Alto Neuroscience Expands ALTO-207 Program with New Phase 3 Trial Amid Q2 Loss
ANRO has more than doubled off its 52-week low of $3.02.
Summary
Alto Neuroscience reported Q2 2026 results with a $27.6M net loss, announced a new Phase 3 monotherapy trial for ALTO-207, and confirmed pro forma cash of $338M funding operations through 2030.
Key Events · Earnings and Guidance · ANRO
-
Q2 2026 Financial Results
Net loss widened to $27.6 million from $17.7 million in Q2 2025. R&D expenses rose to $22.1 million from $13.1 million, reflecting increased clinical development activity.
-
ALTO-207 Program Expansion
A new Phase 3 monotherapy trial (PACE-3) in treatment-resistant depression is planned, with initiation expected in 2H 2027. This adds to the ongoing Phase 2b adjunctive trial and planned Phase 3 adjunctive trial (PACE-2).
-
Positive Independent Data
Nature Medicine published PRIME-PRAXOL trial results showing pramipexole significantly reduced anhedonia (Hedges' g=0.62, p=0.006), reinforcing the dopaminergic mechanism behind ALTO-207.
-
Cash Runway Extended to 2030
Pro forma cash of approximately $338 million after the July 2026 $100 million offering is expected to fund planned operations through 2030.
Analysis · ANRO · Life Sciences
The headline number is a wider Q2 net loss of $27.6 million, but the strategic development is the expansion of the lead program ALTO-207. A third Phase 3 trial—this one as a monotherapy in treatment-resistant depression—has been added to the plan, supported by positive independent data published in Nature Medicine. With pro forma cash of $338 million, the company now expects runway through 2030, funding all three trials. For a clinical-stage biotech, this is a meaningful update: the pipeline is broadening, and the cash position removes near-term financing risk.
At the time of this filing, ANRO was trading at $29.18 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $3.02 to $29.70. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.